All In Biotech

Drug Trial Radar · NCT05103358

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

128

Actual

Start

Mar 10, 2022

Primary completion

Dec 23, 2024

Study completion Dec 23, 2024

Sponsor

Lead sponsor
Aadi Bioscience, Inc.Industry
Sponsor type
Industry
First posted
Nov 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

Conditions

  • Tumor
  • Tumor, Solid
  • Metastasis
  • Metastatic Cancer
  • Cancer
  • Cancer Metastatic
  • Tumors
  • Neoplasms
  • Neoplasm Metastasis
  • Solid Tumor
  • Advanced Solid Tumor
  • Advanced Cancer
  • Malignant Solid Tumor
  • Malignant Solid Neoplasm
  • Malignant Neoplasm
  • Malignant Tumor
  • TSC
  • TSC1
  • TSC2
  • Metastatic Solid Tumor
  • Metastatic Neoplasm

Interventions

  • nab-sirolimusDrug

    Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression , up to 30 months.

Locations

166 sites in 3 countries. Site status is shown where the registry gives one.

  • Alabama Oncology

    Birmingham, Alabama

  • Southern Cancer Center

    Mobile, Alabama

  • Arizona Oncology Associates

    Goodyear, Arizona

  • Honor Health

    Phoenix, Arizona

  • Arizona Oncology Associates

    Prescott Valley, Arizona

  • Yuma Regional Medical Center

    Yuma, Arizona

  • PCR Oncology

    Arroyo Grande, California

  • Nextgen Oncology

    Beverly Hills, California

  • City of Hope

    Duarte, California

  • Providence Medical Foundation (Fullerton)

    Fullerton, California

  • MemorialCare

    Long Beach, California

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCLA - Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Providence Medical Foundation (Napa)

    Napa, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Sharp HealthCare

    San Diego, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Ridley-Tree Cancer Center

    Santa Barbara, California

  • Sarcoma Oncology Research Center

    Santa Monica, California

  • Providence Medical Foundation

    Santa Rosa, California

  • Stanford Cancer Center

    Stanford, California

  • The Oncology Institute of Hope & Innovation

    Whittier, California

  • Rocky Mountain Cancer Centers

    Aurora, Colorado

  • Rocky Mountain Cancer Centers

    Boulder, Colorado

  • Rocky Mountain Cancer Centers

    Colorado Springs, Colorado

  • Rocky Mountain Cancer Centers (Williams St)

    Denver, Colorado

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Rocky Mountain Cancer Centers

    Lakewood, Colorado

  • Rocky Mountain Cancer Centers

    Littleton, Colorado

  • Rocky Mountain Cancer Centers

    Lone Tree, Colorado

  • Rocky Mountain Cancer Centers

    Longmont, Colorado

  • Rocky Mountain Cancer Centers

    Pueblo, Colorado

  • Rocky Mountain Cancer Centers

    Thornton, Colorado

  • Hartford Healthcare

    Hartford, Connecticut

  • Eastern Connecticut Hematology and Oncology

    Norwich, Connecticut

  • Florida Cancer Specialists - North Division

    Altamonte Springs, Florida

  • Florida Cancer Specialists - South Division

    Bonita Springs, Florida

  • Florida Cancer Specialists - South Division

    Bradenton, Florida

  • Florida Cancer Specialists - South Division

    Bradenton, Florida

  • Florida Cancer Specialists - North Division

    Brandon, Florida

Showing 40 of 166 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.